Trials / Completed
CompletedNCT00230763
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0.005% / Timolol 0.5% Fixed Combination (Xalacom) In Previously Treated Patients With Open Angle Glaucoma Or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 396 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's medical history, family history of OAG or OHT, concomitant systemic treatment with beta-blockers, etiology, IOP at baseline, corneal thickness, compliance, and adverse events).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | GSS questionnaire | D0, D30 and D84 |
| PROCEDURE | IOP | D0, D30 and D84 |
| DRUG | LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION | in the evening during 84 days |
| PROCEDURE | Visual acuity | D0 and D84 |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2005-10-03
- Last updated
- 2021-02-18
Locations
102 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00230763. Inclusion in this directory is not an endorsement.